In the emergency department (ED), where clinicians often fly blind against a shifting tide of synthetic opioid cases, a new tool has emerged to bridge the gap between suspicion and certainty.
Labcorp announced in April the launch of its Fentanyl Urine Visual Test, the first FDA-cleared rapid fentanyl test of its kind manufactured in the United States. Available through the newly rebranded Labcorp Point of Care (formerly MEDTOX Diagnostics), the test provides a preliminary result in just 10 minutes—a critical timeframe for medical teams managing potential overdoses.
A growing shadow
The release comes at a time when the shadow of fentanyl is lengthening across the clinical landscape. Labcorp’s own data reveals the reality. Between 2024 and 2025, approximately 4% of pre-employment screenings returned positive for fentanyl. More alarming is the prevalence in clinical settings, where nearly 10% of patients undergoing treatment for opioid use disorder tested positive.
Unlike traditional opiate screens that often miss synthetic variants such as fentanyl, this new test targets norfentanyl, the primary metabolite of fentanyl. By focusing on this byproduct, the test extends the detection window to 48 hours. This is particularly significant, as fentanyl can clear a patient's system in just a few hours.
ADLM guidance: Modernizing the "standard" screen
The launch aligns with the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Guidance Document on Laboratory Testing for Drugs of Misuse, which was updated to reflect the evolving toxicity of the American drug supply.
The ADLM guidance highlights several critical shifts in how hospitals should approach toxicology:
- Fentanyl as a core requirement: The ADLM now "strongly recommends" that fentanyl testing be available at all facilities supporting an ED.
- Addressing the opiate myth: The guidance emphasizes that standard opiate immunoassays—which typically detect morphine and codeine—frequently fail to detect synthetic opioids like fentanyl.
- Clinical utility: While rapid tests are presumptive, the ADLM notes their value downstream management, such as social service involvement in pediatric cases or behavioral health referrals for adults.
"When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care," Brian Caveney, MD, chief medical and scientific officer at Labcorp, said in a news release. "The test delivers results in minutes... ultimately supporting better patient outcomes."
The reality of rapid testing
While the 10-minute turnaround offers immediate insight, the medical community maintains a cautious stance. Per standard practice and FDA clearance, the results of the Fentanyl Urine Visual Test are considered preliminary. The ADLM guidance continues to advocate for confirmatory testing (such as mass spectrometry) when results will significantly impact long-term patient care or legal standing.
By moving high-complexity testing capabilities directly to the ED, providers can bypass traditional laboratory bottlenecks. In an overdose crisis defined by its speed, a 10-minute diagnostic window offers a practical advantage for immediate intervention.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
